MAPK3 and rheumatoid arthritis: Western blot confirmed that the three could down-regulate the expression of SRC, STAT3, and MAPK3 proteins, which are the core targets predicted by network pharmacology, and verified the molecular mechanism that ARSHs exerted anti-RA effects by regulating apoptosis-related targets and signaling pathways.